SCHEMBL15968423

SCHEMBL15968423

CC(=O)[C@H]1C[C@@H](CCO)C1(C)C

nearest known ligand 0.40

Predicted protein targets (top 1)

geneUniProtsupporting neighboursconfidence
CD81 P60033 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18723756 1.00 CD81 (0.32) CD81
SCHEMBL18723626 1.00 CD81 (0.32) CD81
SCHEMBL13397368 0.84 CD81 (0.32) CD81
SCHEMBL18723519 0.84 CD81 (0.32) CD81
SCHEMBL4332200 0.82 CD81 (0.31) CD81
SCHEMBL18723524 0.79 ATM (0.41)
SCHEMBL13784909 0.79 EPHX2 (0.33)
SCHEMBL4334479 0.79 CD81 (0.33) CD81
SCHEMBL13784912 0.77 ALDH1A1 (0.36)
SCHEMBL4905394 0.76 GRM2 (0.38) CD81

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2747886-B1 SELECTIVE HYDROGENATION OF ALDEHYDE WITH RU/BIDENTATE LIGANDS COMPLEXES FIRMENICH & CIE (CH) 2018-11-14 EP disclosed
EP-2970067-B1 SELECTIVE HYDROGENATION OF ALDEHYDES WITH RU/BIDENTATE LIGANDS COMPLEXES FIRMENICH & CIE (CH) 2017-08-16 EP disclosed
US-9714263-B2 Selective hydrogenation of aldehydes with Ru/bidentate ligands complexes FIRMENICH SA (CH) 2017-07-25 US disclosed
US-20160039853-A1 SELECTIVE HYDROGENATION OF ALDEHYDES WITH RU/BIDENTATE LIGANDS COMPLEXES FIRMENICH SA (CH) 2016-02-11 US disclosed
US-9090534-B2 Selective hydrogenation of aldehyde with ru/bidentate ligands complexes FIREMENICH SA (CH) 2015-07-28 US disclosed
US-9090534-B2 Selective hydrogenation of aldehyde with ru/bidentate ligands complexes FIREMENICH SA (CH) 2015-07-28 US disclosed
US-9090534-B2 Selective hydrogenation of aldehyde with ru/bidentate ligands complexes FIREMENICH SA (CH) 2015-07-28 US disclosed
US-20140243526-A1 SELECTIVE HYDROGENATION OF ALDEHYDE WITH RU/BIDENTATE LIGANDS COMPLEXES FIRMENICH SA (CH) 2014-08-28 US disclosed
US-20140243526-A1 SELECTIVE HYDROGENATION OF ALDEHYDE WITH RU/BIDENTATE LIGANDS COMPLEXES FIRMENICH SA (CH) 2014-08-28 US disclosed
US-20140243526-A1 SELECTIVE HYDROGENATION OF ALDEHYDE WITH RU/BIDENTATE LIGANDS COMPLEXES FIRMENICH SA (CH) 2014-08-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160039853-A1 SELECTIVE HYDROGENATION OF ALDEHYDES WITH RU/BIDENTATE LIGANDS COMPLEXES ADH5, ADH1A, ADH1C CD81 1439/4885
US-20140243526-A1 SELECTIVE HYDROGENATION OF ALDEHYDE WITH RU/BIDENTATE LIGANDS COMPLEXES ADH5, ADH1A, HAO2 CD81 690/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.